[Correlation between TGF- β1 expression and Treg cell infiltration in glioma]. 2011

Guan-hua Zhang, and Xiao-bing Jiang, and Xiang-heng Zhang, and Ke Sai, and Qun-ying Yang, and Zhong-ping Chen, and Yong-gao Mou
Department of Neurosurgery, Cancer Center, State Key Laboratory of Oncology in South China, Sun Yat-sen University, Guangzhou 510060, China. gh_zhang@yeah.net

OBJECTIVE To investigate correlation between the expression of TGF-β1 and the amount of Treg cell in glioma, and evaluate their clinical values in predicting the prognosis of glioma. METHODS Double immunohistochemistry staining was used to detect the expression of TGF-β1, CD4 and Foxp3 in 135 specimens of human gliomas (WHO I 18, WHO II 45, WHO III 53, WHO IV 19) and 15 normal brain. RESULTS OF the 135 specimans of glioma, 58 showed low TGF-β1 expression and 77 (57.03%) showed high TGF-β1 expression while ws not expression in normal brain tissue. Average Treg cell density in glioma was 2. 031/HP, but there was no expression of Treg in normal brain tissue. Expression of TGF-β1 was positively correlated with the mount of Treg in glioma tissues (r = 0.294, P < 0.01). Compared with the low grade, The levels of TGF-β1 and the amount of Treg cells with significant higher in high-grade glioma, however the mount of Treg had no correlations with Sex, KPS score. The Laplan-Meier analysis showed that there wer significant difference in overall survival (OS) between the TGF-β1 high-expression and low-expression group (P < 0.001). Cox multivariate analysis showed that TGF-β1 and Treg were not independent prognostic factors (P > 0.05). CONCLUSIONS Intratumoral of TGF-β1 may relate to the infiltration of Treg cells in glioma tissues. The level of TGF-β1 was obviously increased in high grade. Glioma patients with TGF-β1 or Trg high expression have poorer prognosis, while TGF-β1 and Treg cannot serve as independent prognostic factors of glioma survival time.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D005910 Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21) Glial Cell Tumors,Malignant Glioma,Mixed Glioma,Glial Cell Tumor,Glioma, Malignant,Glioma, Mixed,Gliomas,Gliomas, Malignant,Gliomas, Mixed,Malignant Gliomas,Mixed Gliomas,Tumor, Glial Cell,Tumors, Glial Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Guan-hua Zhang, and Xiao-bing Jiang, and Xiang-heng Zhang, and Ke Sai, and Qun-ying Yang, and Zhong-ping Chen, and Yong-gao Mou
October 2012, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Guan-hua Zhang, and Xiao-bing Jiang, and Xiang-heng Zhang, and Ke Sai, and Qun-ying Yang, and Zhong-ping Chen, and Yong-gao Mou
December 2017, Experimental oncology,
Guan-hua Zhang, and Xiao-bing Jiang, and Xiang-heng Zhang, and Ke Sai, and Qun-ying Yang, and Zhong-ping Chen, and Yong-gao Mou
September 2016, Journal of neurosurgical sciences,
Guan-hua Zhang, and Xiao-bing Jiang, and Xiang-heng Zhang, and Ke Sai, and Qun-ying Yang, and Zhong-ping Chen, and Yong-gao Mou
April 2010, Chinese journal of cancer,
Guan-hua Zhang, and Xiao-bing Jiang, and Xiang-heng Zhang, and Ke Sai, and Qun-ying Yang, and Zhong-ping Chen, and Yong-gao Mou
December 2011, Immunotherapy,
Guan-hua Zhang, and Xiao-bing Jiang, and Xiang-heng Zhang, and Ke Sai, and Qun-ying Yang, and Zhong-ping Chen, and Yong-gao Mou
January 2015, Current health sciences journal,
Guan-hua Zhang, and Xiao-bing Jiang, and Xiang-heng Zhang, and Ke Sai, and Qun-ying Yang, and Zhong-ping Chen, and Yong-gao Mou
October 2013, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica,
Guan-hua Zhang, and Xiao-bing Jiang, and Xiang-heng Zhang, and Ke Sai, and Qun-ying Yang, and Zhong-ping Chen, and Yong-gao Mou
January 2021, Frontiers in immunology,
Guan-hua Zhang, and Xiao-bing Jiang, and Xiang-heng Zhang, and Ke Sai, and Qun-ying Yang, and Zhong-ping Chen, and Yong-gao Mou
July 2012, Immunotherapy,
Guan-hua Zhang, and Xiao-bing Jiang, and Xiang-heng Zhang, and Ke Sai, and Qun-ying Yang, and Zhong-ping Chen, and Yong-gao Mou
January 2014, Oncology letters,
Copied contents to your clipboard!